Free Radicals and Endothelial Dysfunction: Potential Positive Effects of TNF-α Inhibitors

Overview

Journal Redox Rep

Specialties Biochemistry
Biology
Endocrinology

Date 2013 May 17

PMID 23676793

Citations 28

Authors

Giuseppe Murdaca

Francesca Spano

Paola Cagnati

Francesco Puppo

Affiliations

Soon will be listed here.

Abstract

Objectives: During the last decade many new biological immune modulators have entered the market as new therapeutic principles. Tumor necrosis factor (TNF)-α is a pro-inflammatory cytokine known to a have a key role in the pathogenic mechanisms of various immune-mediated or inflammatory diseases. However, TNF-α also plays a key role in endothelial dysfunction and, thus, in the development and progression of atherosclerosis. What, then, is the potential therapeutic role of TNF-α inhibitors?

Methods: We analysed the current literature concerning the administration of TNF-α inhibitors and their potential benefits upon endothelial function.

Results: TNF-α inhibitors decrease the serum levels of inflammatory markers such as TNF-α itself, CRP, IL-6, and increased the tissue expression of endothelial NO synthase and the vasodilatory response to bradykinin.

Discussion: TNF-α inhibitors may change the progression of endothelial dysfunction and, thus, slow down the atherosclerotic process.

Citing Articles

Lipids, lipid-modified drug target genes, and the risk of male infertility: a Mendelian randomization study.

Li W, Li H, Zha C, Che B, Yu Y, Yang J Front Endocrinol (Lausanne). 2024; 15:1392533.

PMID: 39114294 PMC: 11303150. DOI: 10.3389/fendo.2024.1392533.

Exploring the Mechanism of Asiatic Acid against Atherosclerosis Based on Molecular Docking, Molecular Dynamics, and Experimental Verification.

Wu Z, Yang L, Wang R, Yang J, Liang P, Ren W Pharmaceuticals (Basel). 2024; 17(7).

PMID: 39065817 PMC: 11279847. DOI: 10.3390/ph17070969.

Influence of Race and High Laminar Shear Stress on TNFR1 Signaling in Endothelial Cells.

Aldokhayyil M, Gomez D, Cook M, Kavazis A, Roberts M, Geetha T Int J Mol Sci. 2023; 24(19).

PMID: 37834170 PMC: 10572906. DOI: 10.3390/ijms241914723.

Forced Swimming-Induced Depressive-like Behavior and Anxiety Are Reduced by Chlorpheniramine via Suppression of Oxidative and Inflammatory Mediators and Activating the Nrf2-BDNF Signaling Pathway.

Alamri H, Mufti R, Sabir D, Abuderman A, Dawood A, ShamsEldeen A Curr Issues Mol Biol. 2023; 45(8):6449-6465.

PMID: 37623226 PMC: 10453464. DOI: 10.3390/cimb45080407.

Risk of all-cause and cause-specific mortality associated with immune-mediated inflammatory diseases in Korea.

Kwon O, Lee S, Chun J, Han K, Kim Y, Kim R Front Med (Lausanne). 2023; 10:1185300.

PMID: 37409280 PMC: 10319061. DOI: 10.3389/fmed.2023.1185300.

References

Buttari B, Profumo E, Mattei V, Siracusano A, Ortona E, Margutti P . Oxidized beta2-glycoprotein I induces human dendritic cell maturation and promotes a T helper type 1 response. Blood. 2005; 106(12):3880-7. DOI: 10.1182/blood-2005-03-1201. View

Esdaile J, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, du Berger R . Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2001; 44(10):2331-7. DOI: 10.1002/1529-0131(200110)44:10<2331::aid-art395>3.0.co;2-i. View

Szekanecz Z, Kerekes G, Soltesz P . Vascular effects of biologic agents in RA and spondyloarthropathies. Nat Rev Rheumatol. 2009; 5(12):677-84. DOI: 10.1038/nrrheum.2009.219. View

Profumo E, Buttari B, Alessandri C, Conti F, Capoano R, Valesini G . Beta2-glycoprotein I is a target of T cell reactivity in patients with advanced carotid atherosclerotic plaques. Int J Immunopathol Pharmacol. 2010; 23(1):73-80. DOI: 10.1177/039463201002300107. View

Ridker P, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E . Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation. 2000; 101(18):2149-53. DOI: 10.1161/01.cir.101.18.2149. View

Blank M, Shoenfeld Y . Beta-2-glycoprotein-I, infections, antiphospholipid syndrome and therapeutic considerations. Clin Immunol. 2004; 112(2):190-9. DOI: 10.1016/j.clim.2004.02.018. View

Ciprandi G, Murdaca G, Colombo B, De Amici M, Marseglia G . Serum vascular endothelial growth factor in allergic rhinitis and systemic lupus erythematosus. Hum Immunol. 2008; 69(8):510-2. DOI: 10.1016/j.humimm.2008.05.010. View

Virdis A, Santini F, Colucci R, Duranti E, Salvetti G, Rugani I . Vascular generation of tumor necrosis factor-α reduces nitric oxide availability in small arteries from visceral fat of obese patients. J Am Coll Cardiol. 2011; 58(3):238-47. DOI: 10.1016/j.jacc.2011.01.050. View

Nilsson J, Kovanen P . Will autoantibodies help to determine severity and progression of atherosclerosis?. Curr Opin Lipidol. 2004; 15(5):499-503. DOI: 10.1097/00041433-200410000-00002. View

10.

Hochberg M, Lebwohl M, Plevy S, Hobbs K, Yocum D . The benefit/risk profile of TNF-blocking agents: findings of a consensus panel. Semin Arthritis Rheum. 2005; 34(6):819-36. DOI: 10.1016/j.semarthrit.2004.11.006. View

11.

Gonzalez M, Selwyn A . Endothelial function, inflammation, and prognosis in cardiovascular disease. Am J Med. 2003; 115 Suppl 8A:99S-106S. DOI: 10.1016/j.amjmed.2003.09.016. View

12.

Napoli C, Ignarro L . Nitric oxide and atherosclerosis. Nitric Oxide. 2001; 5(2):88-97. DOI: 10.1006/niox.2001.0337. View

13.

Morrow D, Rifai N, Antman E, Weiner D, McCabe C, Cannon C . C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol. 1998; 31(7):1460-5. DOI: 10.1016/s0735-1097(98)00136-3. View

14.

Buttari B, Profumo E, Petrone L, Pietraforte D, Siracusano A, Margutti P . Free hemoglobin: a dangerous signal for the immune system in patients with carotid atherosclerosis?. Ann N Y Acad Sci. 2007; 1107:42-50. DOI: 10.1196/annals.1381.005. View

15.

Colombo B, Cacciapaglia F, Puntoni M, Murdaca G, Rossi E, Rodriguez G . Traditional and non traditional risk factors in accelerated atherosclerosis in systemic lupus erythematosus: role of vascular endothelial growth factor (VEGATS Study). Autoimmun Rev. 2008; 8(4):309-15. DOI: 10.1016/j.autrev.2008.10.002. View

16.

Weber C, Noels H . Atherosclerosis: current pathogenesis and therapeutic options. Nat Med. 2011; 17(11):1410-22. DOI: 10.1038/nm.2538. View

17.

Taylor P . Antibody therapy for rheumatoid arthritis. Curr Opin Pharmacol. 2003; 3(3):323-8. DOI: 10.1016/s1471-4892(03)00032-8. View

18.

Ridker P, Cushman M, Stampfer M, Tracy R, Hennekens C . Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997; 336(14):973-9. DOI: 10.1056/NEJM199704033361401. View

19.

Arvieux J, Regnault V, Hachulla E, Darnige L, Berthou F, Youinou P . Oxidation of beta2-glycoprotein I (beta2GPI) by the hydroxyl radical alters phospholipid binding and modulates recognition by anti-beta2GPI autoantibodies. Thromb Haemost. 2001; 86(4):1070-6. PMC: 3273196. DOI: 10.1186/ar251. View

20.

Arenas I, Armstrong S, Xu Y, Davidge S . Chronic tumor necrosis factor-alpha inhibition enhances NO modulation of vascular function in estrogen-deficient rats. Hypertension. 2005; 46(1):76-81. DOI: 10.1161/01.HYP.0000168925.98963.ef. View